The EMS Group has signed an agreement to purchase 100% of Medley, one of Brazil's leading generic drug brands, from the French pharmaceutical giant Sanofi. This deal aims to leverage Medley's strong presence in the Brazilian generic market alongside EMS's industrial and production capabilities. Although the specific financial details of the transaction have not been disclosed, this acquisition highlights EMS's strategic move to expand its influence in the competitive pharmaceutical landscape of Brazil.

Medley has established itself as a significant player in the generic drug sector in Brazil, providing low-cost medication options and holding the second position among pharmaceutical manufacturers in the country. The acquisition is seen as an opportunity for EMS to enhance its portfolio with Medley's extensive range of products, which could provide consumers with more affordable medication choices in the long run. The development comes amid a bidding war, with several other laboratories, including Sun Pharma and Hypera, showing interest in acquiring the Medley brand.

The manufacturing facility located in Campinas, São Paulo, positions Medley as a key asset in EMS's growth strategy. By integrating Medley's production operations and market reach, EMS is poised to strengthen its foothold in the Brazilian pharmaceutical market, which has been evolving rapidly due to increasing demand for generic medications. This acquisition is expected to not only benefit the companies involved but also enhance access to essential medicines for Brazilian consumers.